The Antidote - Taking a Look at Corporate Inversions and e-Health
Add bookmark
Summer is at an end and whilst corporate activity continued apace, including AbbVie acquiring Shire, Omega Pharma attracting acquisition interest, and GSK and Sanofi seeking to dispose of certain of their older drugs, some of you have been cooling off with the ALS Ice Bucket Challenge! This icy event not only brought attention to this rare disease,
but highlighted that the drug development pipeline for ALS needed to be bolstered, and reminded us of the high level of costs associated with drug development, particularly if a drug fails. Let’s see whether this innovative, albeit chilly, approach to raise awareness encourages more companies to look to drug development.
